Veritas In Silico Co. targets low molecular weight drugs interacting with cellular nucleic acids

The Tokyo-based company was established in November 2016 with the aim to find new therapies based on low-molecular weight drug discovery targeting nucleic acids. Investment is from several Mitsubishi Group companies.

VIS URL http://www.veritasinsilico.com/index.html

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny